
Opinion|Videos|August 30, 2024
Challenges in Risk Assessment and Biomarkers in Treatment Recommendations
The panelists examine the challenges and limitations they've faced when using the Gleason score for risk assessment in prostate cancer patients, while also highlighting how biomarker testing has informed and guided their treatment strategies.
Advertisement
Episodes in this series

Video content above is prompted by the following question:
- What are some challenges or limitations you have encountered when using the Gleason score when assessing risk in your prostate cancer patients?
- In your clinical experience, have biomarkers guided your treatment recommendations? If so which one(s)?
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA grants clearance to Hugo robotic-assisted surgery system for urologic procedures
2
Apalutamide is linked to fewer CNS-related conditions in patients with nmCRPC
3
Prostate MRI is linked with higher sensitivity, NPV vs micro-ultrasound in pilot study
4
BOND-003: Cretostimogene yields durable 24-month responses in high-grade NMIBC
5























